GSK is acquiring Boston Pharmaceuticals’ efimosfermin, which posted Phase 2 results showing improvement in fibrosis and resolution of MASH. GSK said this fusion protein will complement an siRNA drug it is currently developing for liver diseases.
The post GSK Makes a Big Liver Disease Move With $1.2B Deal for Phase 3-Ready MASH Drug appeared first on MedCity News.
